PRESENTATION

Q2 2026 — Results presentation

Q2 2026PDF · 24 pages5.2 MB


-- 1 of 24 --

2 nd Quarter 2026
Earnings Call
July 15, 2026

-- 2 of 24 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased
scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from
the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in
the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of
new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 24 --

Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab
A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc.
relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences
Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partner with Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was
discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding
agreement with Royalty Pharma plc
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.
Other
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with
Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion
agreement with Nippon Shinyaku in Japan
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 24 --

CEO Remarks
Sales performance and earnings review
Capital allocation and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Ryan Koors
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 24 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 24 --

7
Q2 Earnings Summary
5.6%
operational sales
growth 1,2
Six key businesses driving growth
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Includes an approximate (460) basis point headwind from STELARA

-- 7 of 24 --

Innovative Medicine: 6.8% operational sales growth 1,2
8
Oncology 	Neuroscience	Immunology
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Includes an approximate (760) basis point headwind from STELARA
Note: Includes existing products and planned future launches

-- 8 of 24 --

MedTech: 3.6% operational sales growth1
9
Cardiovascular 	Surgery 	Vision
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
Impella® Heart
Pump Technology
OTTAVA
Robotic
Surgical
System
ETHICON 	4000
Surgical Stapler
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
MONARCH
Flexible Robotics
Platform
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Includes existing products and planned future launches

-- 9 of 24 --

Leading the next wave of
healthcare innovation
10

-- 10 of 24 --

Ryan Koors
Vice President,
Investor Relations

-- 11 of 24 --

Regional sales results 	Q2 2026 	Q2 2025
% Change
Reported 	Operational 1
U.S. 	$14.5 	$13.5 	7.3% 	7.3%
Europe 	5.7 	5.4 	6.3 	3.3
Western Hemisphere
(ex U.S.) 1.3 	1.2 	8.5 	2.7
Asia-Pacific, Africa 	3.7 	3.6 	3.8 	3.9
International 	10.8 	10.2 	5.7 	3.4
Worldwide (WW) 	$25.3 	$23.7 	6.6% 	5.6%
Dollars in billions
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded
2nd Quarter 2026 sales
12

-- 12 of 24 --

$25.3
$23.7
$7.1 	$6.7
4.7%; 3.2% 1
$2.90 $2.77
Dollars in billions, except EPS
Reported %; Operational %1
Sales
Adjusted earnings2 	Adjusted EPS 2
6.6%; 5.6% 1
GAAP earnings
5.7%
Q2 2026 	Q2 2025
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
2nd Quarter 2026 financial highlights
GAAP EPS
13
Q2 2026 	Q2 2025 	Q2 2026 	Q2 2025
Q2 2026 	Q2 2025 	Q2 2026 	Q2 2025
(0.1)% 	(0.9)%
$5.5 	$5.5 	$2.27 	$2.29

-- 13 of 24 --

Other
$2,795
Neuroscience
$2,337
Oncology
$7,406 Immunology
$3,844
■ Reported growth 	■ Operational growth1
$16,384
7.8%, 6.8%
WW sales $MM
Key drivers of operational performance 1
Oncology
• 	DARZALEX increase primarily driven by strong share gains and market growth
• 	CARVYKTI increase driven by share gains and continued site expansion
• 	TECVAYLI growth driven by launch uptake, share gains following U.S. TECVAYLI +
DARZALEX FASPRO approval, and from expansion in the community setting
• 	TALVEY growth driven by share gains from expansion in the community setting
• 	RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains
• 	ERLEADA increase driven by continued share gains in mCSPC and market growth,
partially offset by unfavorable patient mix and inventory dynamics
• 	IMBRUVICA decrease driven by share loss due to continued competitive pressure
and unfavorable patient mix
Immunology
• 	TREMFYA growth due to share gains across all indications with significant IBD launch
momentum and market growth
• 	SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar
competition, and unfavorable patient mix, partially offset by market growth
• 	STELARA decline driven by the impact of biosimilar competition, increasing adoption
of novel classes, and unfavorable patient mix
• 	OTHER IMMUNOLOGY increase driven by IMAAVY and ICOTYDE in the U.S.
Neuroscience
• 	SPRAVATO growth driven by continued increased physician and patient demand
• 	CAPLYTA growth driven by strong continued momentum in the aMDD launch
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily
driven by favorable patient mix, partially offset by share loss and inventory dynamics
Other
• 	UPTRAVI increase driven by market and share growth, partially offset by unfavorable
patient mix
• 	OPSUMIT/OPSYNVI growth driven by share gains and market growth, partially
offset by U.S. LOE-related inventory burn
• 	PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA decrease driven by declines in
share and market, partially offset by favorable patient mix
• 	XARELTO increase driven by favorable patient mix, partially offset by continued
share erosion
Adjusted operational sales 2 : WW 6.9%, U.S. 8.9%, Int’l 3.8%
Innovative Medicine highlights – 2nd quarter 2026
Reported: 	WW 7.8%, U.S. 8.9%, Int’l 6.0%
Operational 1: 	WW 6.8%, U.S. 8.9%, Int’l 3.6%
(3.7)%, (4.6)%	17.3%, 16.1%
(1.8)%, (2.4)%
Strong operational growth 1 of 6.8% driven primarily by new product launches
14.0%, 13.4%
14
Stelara impacted results 1 by ~(760) basis points
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded

-- 14 of 24 --

Key drivers of operational performance 1
Cardiovascular
• 	Electrophysiology: Increase driven by procedure growth, commercial execution, new
product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL), partially
offset by competitive pressures in PFA and China inventory dynamics
• 	Abiomed: Decline driven by lower U.S. procedure volumes, partially offset by
continued OUS growth including sustained adoption of Impella 5.5
• 	Shockwave: Double-digit growth driven by continued strong adoption of Coronary
and Peripheral portfolios and new product launches (AERO C2)
Surgery
• 	Advanced:
• 	Biosurgery: ~ +9% growth driven by continued strength of the portfolio and
commercial execution, partially offset by the impact of the surgery
transformation program and VBP in China
• 	Endocutters: ~ -5% due to competitive pressures and VBP in China
• 	Energy: ~ -1% driven by impact of the surgery transformation program, VBP in
China, and competitive pressures, partially offset by new product launches
• 	General: Increase primarily due to technology penetration and upgrades within our
differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market
expansion, partially offset by VBP in China
Vision
• 	Contact Lenses/Other: Increase driven by strong performance of the ACUVUE
OASYS 1-Day family of products including recent launches and strategic price actions,
partially offset by inventory dynamics
• 	Surgical: Growth driven by strength of recent product innovations, robust demand for
premium IOLs, and strong commercial execution, partially offset by competitive
pressures in the U.S.
Orthopaedics
Growth across all platforms primarily driven by new product launches and strong
commercial execution:
• 	Hips: Increase driven by new product launches (EMPHASYS)
• 	Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull
through related to the VELYS Robotic assisted solutions
• 	Trauma: Growth driven by recently launched products (VOLT)
• 	Spine, Sports & Other: Increase driven by new product innovations as well as growth
in shoulders, partially offset by competitive pressures and inventory dynamics
Adjusted operational sales 2 : WW 3.7%, U.S. 4.1%, Int’l 3.2%
Surgery
$2,653
Orthopaedics
$2,418
Vision
$1,451
Cardiovascular
$2,404
■ Reported growth 	■ Operational growth 1
$8,926
4.5%, 3.6%
WW sales $MM
Solid operational growth1 of 3.6% driven primarily by commercial execution and innovation
Reported: 	WW 4.5%, U.S. 3.9%, Int’l 5.2%
Operational 1: 	WW 3.6%, U.S. 3.9%, Int’l 3.2%
4.0%, 3.1%
6.0%, 5.6%
3.9%, 2.3%
4.9%, 4.2%
MedTech highlights – 2nd quarter 2026
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website
Note: Values may be rounded 	15

-- 15 of 24 --

2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$25,310 	100.0 	$23,743 	100.0 	6.6
Cost of products sold 	8,051 	31.8 	7,628 	32.1 	5.5
Gross Profit 	17,259 	68.2 	16,115 	67.9 	7.1
Selling, marketing and administrative expenses 	6,432 	25.4 	5,889 	24.8 	9.2
Research and development expense 	3,653 	14.4 	3,516 	14.8 	3.9
Interest (income) expense, net 	62 	0.2 	48 	0.2
Other (income) expense, net 	331 	1.3 	107 	0.5
Restructuring 	34 	0.2 	64 	0.3
Earnings before provision for taxes on income 	6,747 	26.7 	6,491 	27.3 	3.9
Provision for taxes on income 	1,213 	4.8 	954 	4.0 	27.1
Net Earnings 	$5,534 	21.9 	$5,537 	23.3 	(0.1)
Net earnings per share (Diluted) 	$2.27 	$2.29 	(0.9)
Average shares outstanding (Diluted) 	2,440.1 	2,419.1
Effective tax rate 	18.0% 	14.7%
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$8,660 	34.2 	$8,188 	34.5 	5.8
Net earnings 	$7,081 	28.0 	$6,699 	28.2 	5.7
Net earnings per share (Diluted) 	$2.90 	$2.77 	4.7
Effective tax rate 	18.2% 	18.2%
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
(Unaudited; Dollars and shares in millions except per share figures)
16
2 nd Quarter 2026
Condensed consolidated statement of earnings

-- 16 of 24 --

Innovative Medicine 2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$16,384 	100.0 	$15,202 	100.0 	7.8
Cost of products sold 	3,505 	21.4 	3,180 	20.9 	10.2
Gross Profit 	$12,879 	78.6 	$12,022 	79.1 	7.1
Selling, marketing and administrative expenses 	3,130 	19.1 	2,789 	18.3 	12.2
Research and development expense 	2,875 	17.5 	2,869 	18.9 	0.2
Other segment items 1 	(84) 	(0.5) 	(129) 	(0.8)
Adjusted segment income before tax 2 	$6,958 	42.5 	$6,493 	42.7 	7.2
(Unaudited; Dollars in millions)
Adjusted earnings before provision for taxes on income by segment
17
MedTech 2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$8,926 	100.0 	$8,541 	100.0 	4.5
Cost of products sold 	3,236 	36.3 	3,142 	36.8 	3.0
Gross Profit 	$5,690 	63.7 	$5,399 	63.2 	5.4
Selling, marketing and administrative expenses 	3,052 	34.2 	2,862 	33.4 	6.6
Research and development expense 	776 	8.7 	690 	8.1 	12.5
Other segment items 1 	(105) 	(1.2) 	(53) 	(0.6)
Adjusted segment income before tax 2 	$1,967 	22.0 	$1,900 	22.2 	3.5
Enterprise 2026 	2025 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Adjusted income before tax 2 	$8,660 	34.2 	$8,188 	34.5 	5.8
2 nd Quarter 2026
1 Includes other Income and Expense
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website

-- 17 of 24 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 18 of 24 --

Capital allocation
Organic growth business needs
Free cash flow 1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Dollars in billions 	Q2 2026
Cash and marketable
securities $20.8
Debt 	($49.0)
Net debt 	($28.2)
Free cash flow1,2 ~$8.7
Q2 2026:
$3.7B invested in R&D
$7.2B year-to-date
$3.3B in dividends paid
to shareholders
$6.4B year-to-date
Note: Values may be rounded
1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 Estimated as of July 15, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
19

-- 19 of 24 --

Operational2 sales guidance of 6.8% and adjusted operational EPS 2,4 at 7.3% (midpoints)
July 2026 	April 2026 	Comments
Adjusted operational sales 1,2 	6.2% - 6.8% 	5.6% - 6.6% Tightening range;
Increasing midpoint to 6.5%
Operational sales 2 	$100.3B - $100.9B
6.5% - 7.1%
$99.7B - $100.7B
5.9% - 6.9%
Tightening range;
Increasing midpoint by $0.4B to 6.8%
Estimated reported sales 3 	$100.8B - $101.4B
7.0% - 7.6%
$100.3B - $101.3B
6.5% - 7.5%
Tightening range;
Increasing midpoint by $0.3B to 7.3%
FX impact of ($0.1B) or (0.1)%
Adjusted pre-tax
operating margin4,5 	Increase of approximately 75 bps 	Increase of at least 50 bps 	Increasing
Net other income 4 	$1.0 - $1.2 billion 	$1.0 - $1.2 billion 	Maintaining
Net interest expense / (income) 	$250 - $350 million 	$300 - $400 million 	Decreasing
Effective tax rate 4 	17.0% - 18.0% 	17.5% - 18.5% 	Decreasing
Adjusted EPS (operational) 2,4 	$11.50 - $11.65
6.6% - 8.0%
$11.30 - $11.50
4.7% - 6.7%
Tightening range;
Increasing midpoint by $0.18 to 7.3%
Adjusted EPS (reported) 3,4 	$11.60 - $11.75
7.5% - 8.9%
$11.45 - $11.65
6.1% - 8.1%
Tightening range;
Increasing midpoint by $0.13 to 8.2%
FX impact of ($0.05) or (0.5)%
2026 P&L guidance
1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17
Note: Values may be rounded 	20

-- 20 of 24 --

Innovative Medicine
Anticipated 2026 milestones1 driving long-term value creation
MedTech
21
TECVAYLI + TALVEY in RRMM
Pasritamig in prostate cancer
JNJ-6143 in prostate cancer
INLEXZO in HR NMIBC
ICOTYDE in PsA
CAPLYTA in bipolar mania
TREMFYA in PsA SD
nipocalimab in WAIHA and SLE
Dual Energy THERMOCOOL STSF
C2 Aero Catheters
VARIPULSE Pro
OTTAVA
ETHICON 4000
TECNIS PureSee IOL
MONARCH Urology
VOLT suite of products
1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches
RRMM: Relapsed/refractory multiple myeloma; HR NMIBC: High-risk non-muscle invasive bladder cancer; PsA: Psoriatic arthritis; PsA SD: Psoriatic arthritis structural damage; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; STSF: SMARTTOUCH Surround Flow; IOL:
Intraocular lens

-- 21 of 24 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Ryan Koors
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 22 of 24 --

Slide footer goes here if required 	23

-- 23 of 24 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
 	US TREMFYA (guselkumab) 	 	US nipocalimab 	US ERLEADA (apalutamide) 	 	ICOTYDE (icotrokinra) 	ERLEADA (apalutamide) 	 JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis Structural
Damage (APEX)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
EU Localized Prostate Cancer (ATLAS) 	Psoriasis (ICONIC-ADVANCE
1&2 Update)
Localized Prostate Cancer (ATLAS) 	Ulcerative Colitis (DUET-UC)
 	US ICOTYDE (icotrokinra) 	US CAPLYTA (lumateperone) 	US ERLEADA (apalutamide) 	ICOTYDE (icotrokinra) 	 ERLEADA (apalutamide) 	 JNJ-4804 Co-antibody Therapy
EU Psoriasis (ICONIC) 	Bipolar Mania 	EU High Risk Prostate Cancer (PROTEUS) 	Psoriasis (ICONIC-ASCEND) 	High Risk Prostate Cancer (PROTEUS) 	Crohn's Disease (DUET-CD)
US nipocalimab 	US bleximenib 	icotrokinra 	 TALVEY (talquetamab) 	 JNJ-4804 Co-antibody Therapy
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Relapsed Refractory Acute Myeloid
Leukemia (cAMeLot-1)
Psoriatic Arthritis (ICONIC-
PsA)
Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)
Psoriatic Arthritis (AFFINITY)
AKEEGA (niraparib/abiraterone) 	 	US TALVEY (talquetamab) 	ICOTYDE (icotrokinra) 	TALVEY (talquetamab) 	 nipocalimab
EU M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
 	EU Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)
Psoriasis (ICONIC-TOTAL
Update)
Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)
Systemic Lupus Erythematosus
(JASMINE)
 	US DARZALEX (daratumumab) 	US TALVEY (talquetamab) 	CAPLYTA (lumateperone) 	 TECVAYLI (teclistamab) 	bleximenib
Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)
Bipolar Mania (ITI-007-452) 	Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
 	US TECVAYLI (teclistamab) 	 	US TECVAYLI (teclistamab) 	 	nipocalimab
INLEXZO (gemcitabine intravesical
delivery system) 	pasritamig + JNJ-9401
EU Multiple Myeloma 1-3PLs
(MajesTEC-3)
 	EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
High Risk Non Muscle Invasive Bladder
Cancer BCG Experienced (SunRISe-5)
Prostate Cancer (PCR1001)
TECVAYLI (teclistamab) 	TECVAYLI (teclistamab) 	JNJ-6143 (HLD-0915)
EU Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)
 	EU Multiple Myeloma 1-3PLs (MajesTEC-3) 	Prostate Cancer (FIH Update)
 	US RYBREVANT (amivantamab)
Head and Neck Cancer (ORIGAMI-4)
US
INLEXZO (gemcitabine intravesical
delivery system)
EU High Risk Non Muscle Invasive Bladder
Cancer BCG Experienced (SunRISe-5)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2026*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and
assets and does not guarantee continued investment. This information is as of July 15, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= Achieved

-- 24 of 24 --